T-NeuroDx
- Company typePrivate
- Founded2018
- HeadquartersAlbuquerque, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
T-NeuroDx firmographics
Firmographics- Name
- T-NeuroDx
- Website
- https://tneurodx.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
T-NeuroDx industry classification
Industry- Product category
- Neurological Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
Keywords
Where T-NeuroDx is headquartered
LocationHeadquarters
- HQ city
- Albuquerque
- HQ country
- United States
- HQ region
- North America
Markets served
T-NeuroDx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
T-NeuroDx product offering
Product offeringCore offering
T-NeuroDx develops blood-based diagnostic tests aimed at the early detection of neurological disorders, with a primary focus on Alzheimer's disease. The company is building proprietary biomarker-based assays that enable non-invasive, blood-drawn screening for neurodegenerative conditions, targeting clinical and research use in neurology and aging-population care.
Product overview
No product information available. The company's website (tneurodx.com) displays only a placeholder/verification page with no accessible content regarding products, services, or technology offerings.
Differentiator
Problem solved
Functional benefit
Products and services
- Blood-Based Alzheimer's Diagnostic Test
Quantifiable outcome
- 12 indigenous foundation models developed from over 500 proposals
Companies that use T-NeuroDx
Customer profileSegments2 records
Ideal customer profiles1 record
T-NeuroDx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
T-NeuroDx partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- IndiaAI MissioncoreT-NeuroDx (NeuroDX) is one of 12 selected Indian startups under the IndiaAI Mission developing indigenous foundation models. The mission provides subsidized access to over 10,000 GPUs and supports the development of AI tools tailored for Indian languages, contexts, and sector needs including healthcare, agriculture, and governance.
- IndiaAI Mission ConsortiumcoreT-NeuroDx is part of a consortium of Indian AI companies including Sarvam AI, Soket AI Labs, GupShup, Gan.ai, Fractal Analytics, Tech Mahindra, IIT Bombay's BharatGPT, GenLoop, ZentelQ, and Shodh AI, all developing sovereign AI tools under the government-backed IndiaAI Mission.
Scale indicators3 records
Recent moves2 records
Expansion highlights3 records
T-NeuroDx competitors and assessment
Company assessmentDirect peers
- C2N Diagnostics: Direct competitor offering PrecivityAD, the first commercial blood-based test for amyloid detection to support Alzheimer's diagnosis. Same customer base (neurologists, memory clinics) and same blood-based biomarker modality.
- Fujirebio: Major diagnostics company marketing the Lumipulse G pTau217/β-Amyloid 1-42 plasma assay for Alzheimer's. Directly comparable in product modality (blood biomarkers for AD) and target market.
- Quanterix: Provides ultra-sensitive Simoa biomarker detection platform used by many groups developing blood-based neurological diagnostics. Comparable in biomarker measurement technology and Alzheimer's applications.
- ADx NeuroSciences: Specializes in biomarker assays for neurodegenerative diseases, including Alzheimer's. Direct comparable in assay development for CNS biomarker diagnostics.
Emerging players
- ALZpath: Early-stage company developing a proprietary pTau217 blood-based assay for Alzheimer's detection and treatment monitoring. Comparable emerging-stage diagnostics focus on blood biomarkers for AD.
- Araclon Biotech: Spanish biotech developing blood-based tests (ABtest) for early Alzheimer's detection, including Aβ40 and Aβ42 plasma assays. Closely comparable small-cap blood-based AD diagnostics peer.
Broad incumbents
- Roche Diagnostics: Major diagnostics incumbent with Elecsys Alzheimer's biomarker assays (CSF and plasma) integrated into its cobas platform. Represents the established-scale competitor that T-NeuroDx would need to displace in hospital labs.
- Abbott Diagnostics: Broad diagnostics incumbent developing Alzheimer's blood-based biomarker assays (e.g., ARCHITECT platform). Comparable as large-scale potential partner or competitor with overlapping clinical markets.
- Biogen: Major neuroscience company with leading Alzheimer's franchise (Leqembi, Aduhelm) requiring biomarker-confirmed patient selection. Comparable strategic overlap as both a potential diagnostic partner and a benchmark for AD market dynamics.
Others
- Sengenics: Functional proteomics company offering biomarker discovery and validation services including for neurological and inflammatory conditions. Comparable as an enabling/diagnostic-adjacent technology platform.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
T-NeuroDx social profiles
Digital presenceT-NeuroDx financial estimates
Financial estimateRevenue estimate
Valuation estimate
T-NeuroDx leadership team
Management profileNumber of profiles
Profiles3 records
T-NeuroDx funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
T-NeuroDx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about T-NeuroDx
What does T-NeuroDx do?
T-NeuroDx develops blood-based diagnostic tests aimed at the early detection of neurological disorders, with a primary focus on Alzheimer's disease. The company is building proprietary biomarker-based assays that enable non-invasive, blood-drawn screening for neurodegenerative conditions, targeting clinical and research use in neurology and aging-population care.
When was T-NeuroDx founded?
T-NeuroDx was founded in 2018. It employs 1 to 10 people.
Where is T-NeuroDx based?
T-NeuroDx is headquartered in Albuquerque, United States, in the North America region.
Who are T-NeuroDx's main competitors?
Direct peers on record are C2N Diagnostics, Fujirebio, Quanterix and ADx NeuroSciences. Emerging players are ALZpath and Araclon Biotech. Broad incumbents are Roche Diagnostics, Abbott Diagnostics and Biogen. Sengenics is listed as an others.
Does T-NeuroDx have an API?
No public API is recorded for T-NeuroDx.
What industry is T-NeuroDx in?
T-NeuroDx's product category is Neurological Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 325413 and its SIC code is 2835.